Application

SB-431542 was used to study the correlation of platelet-derived growth factor receptor B expression and TGF-β pathway activation in colorectal tumor cells. It was used to study the role of TGF-β signaling in modulation of extracellular matrix and myoblast differentiation.

Biochem/physiol Actions

SB-431542 inhibits the TGF-β-mediated activation of SMAD proteins, expression of collagen and fibronectin, cell proliferation and cell motility. It does not inhibit kinases that are activated in response to serum or stress such as ERK, p38 or JNK.

Potent and selective inhibitor of transforming growth factor-β superfamily type I activin receptor-like kinase (ALK) receptors.

Features and Benefits

This compound was developed by GlaxoSmithKline. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Legal Information

Sold for research purposes under agreement from GlaxoSmithKline

Packaging

5 mg in glass bottle